Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 14Nivolumab 13Oxaliplatin 12Leucovorin 11Paclitaxel 7Capecitabine 7pembrolizumab 6Radiotherapy 5Cisplatin 5Taxes 4Specimen Handling 4Radiation 4Irinotecan 4Drug Therapy 4dehydroftorafur 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2futibatinib 2Levoleucovorin 2Endoscopy, Digestive System 2Endoscopy 2Carboplatin 2Biopsy 2zolbetuximab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Rosiglitazone × 90 days × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡